Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 8,249 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Risk Clear all
Terminated Phase 1 Interventional

Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)

NCT06158100
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Venetoclax, Azacitidine, Donor Lymphocyte Infusion
Drug · Biological
Lead sponsor
Antonio M Jimenez Jimenez
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 25, 2026, 4:07 PM EDT
Completed Phase 4 Interventional Results available

Maintain Respiratory Muscle Function and Reduce Pneumonia Risk in Cancer Patients

NCT03469271
View directory record Official record
Conditions
Cancer
Interventions
1,25 (OH)2 D3, Inspiratory isometric resistance training, Oral Placebo, Sham Inspiratory Isometric Resistance Training, Threshold Inspiratory Muscle Trainer (IMT)
Drug · Other · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Oct 25, 2026, 4:07 PM EDT
Completed No phase listed Observational Results available

Facilitators and Barriers to Cancer Screening: Stakeholder Perspectives on Implementation

NCT04683744
View directory record Official record
Conditions
Colorectal Cancer Screening
Interventions
Semi-structured interviews-Patients, Semi-structured interviews-Health system
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Oct 25, 2026, 4:07 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Technology Enhanced Family Treatment

NCT03913013
View directory record Official record
Conditions
Mood Disorders, Bipolar Disorder, Major Depression
Interventions
Family-Focused Treatment with MCC App
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
13 Years to 19 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Oct 25, 2026, 4:07 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Group Prenatal Care for Reducing the Risk of STDs in Pregnant Young Women

NCT00271960
View directory record Official record
Conditions
Sexually Transmitted Diseases, HIV Infections
Interventions
CenteringPregnancy, CenteringPregnancyPlus, Usual care
Behavioral
Lead sponsor
Yale University
Other
Eligibility
14 Years to 25 Years · Female only
Enrollment
1,047 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2008
U.S. locations
2
States / cities
New Haven, Connecticut • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 25, 2026, 4:07 PM EDT
Completed Not applicable Interventional

Heart Health After Cancer Treatment (HEART-ACT)

NCT06055803
View directory record Official record
Conditions
Breast Cancer
Interventions
Intake Session, Individual Sessions, Group Sessions, Graduation, Exercise
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 25, 2026, 4:07 PM EDT
Completed Phase 2 Interventional Results available

De-intensification of Radiation & Chemotherapy in Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Ca

NCT01530997
View directory record Official record
Conditions
Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms
Interventions
Intensity Modulated Radiotherapy (IMRT), Cisplatin, Limited surgical evaluation
Radiation · Drug · Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
5
States / cities
Colorado Springs, Colorado • Gainesville, Florida • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Oct 25, 2026, 4:07 PM EDT
Completed Phase 2 Interventional

Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes

NCT00451997
View directory record Official record
Conditions
Leukemia, Myeloid, Myelodysplastic Syndromes
Interventions
Gleevec, Ara-C
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
60 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 25, 2026, 4:07 PM EDT
Recruiting Phase 3 Interventional

A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

NCT07393282
View directory record Official record
Conditions
High Risk Smoldering Multiple Myeloma (HR-SMM)
Interventions
Linvoseltamab, Daratumumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
9
States / cities
Phoenix, Arizona • Atlanta, Georgia • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 25, 2026, 4:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Coconut Oil vs. Commercial Ultrasound Gel In Obstetric Ultrasounds

NCT05653362
View directory record Official record
Conditions
Pregnancy, High Risk
Interventions
Coconut Oil, Commercial Ultrasound Gel
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 2, 2023 · Synced Oct 25, 2026, 4:07 PM EDT
Terminated Phase 4 Interventional Results available

Long Term Safety Study of PRALUENT

NCT03694197
View directory record Official record
Conditions
Heterozygous Familial Hypercholesterolemia, Non-familial Hypercholesterolemia
Interventions
Praluent
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
40 Years to 85 Years
Enrollment
1,389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
57
States / cities
Auburn, Alabama • Mobile, Alabama • Beverly Hills, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Oct 25, 2026, 4:07 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma

NCT02898259
View directory record Official record
Conditions
B Cell Lymphoma, Lymphoma
Interventions
Ixazomib, Lenalidomide, Rituximab
Drug
Lead sponsor
Brian Hill
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 26, 2022 · Synced Oct 25, 2026, 4:07 PM EDT
Completed Not applicable Interventional Results available

Reduction of Risk Factors for ACL Re-injuries Using a Novel Biofeedback Approach

NCT03273673
View directory record Official record
Conditions
Anterior Cruciate Ligament Injury
Interventions
Biofeedback Intervention
Other
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
14 Years to 21 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Blacksburg, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 25, 2026, 4:07 PM EDT
Completed Not applicable Interventional

BerryCare: A Community Engagement Program

NCT03477305
View directory record Official record
Conditions
Cardiovascular Risk Factor
Interventions
Blackberry Consumption
Behavioral
Lead sponsor
Dawn Brewer
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Beverly, Kentucky • Harlan, Kentucky • Lexington, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Oct 25, 2026, 4:07 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Clinical Decision Support for PrEP

NCT05245201
View directory record Official record
Conditions
HIV Infections, Preexposure Prophylaxis (PrEP)
Interventions
Standard of care, Clinical decision support for PrEP
Other
Lead sponsor
Harvard Pilgrim Health Care
Other
Eligibility
15 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Ahoskie, North Carolina • Gastonia, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 25, 2026, 4:07 PM EDT
Completed Phase 2 Interventional

A Prospective Study of Daily Adaptive Radiotherapy to Better Organ-at-Risk Doses in Head and Neck Cancer

NCT04883281
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Intensity modulated radiation therapy (IMRT) with or without chemotherapy, cisplatin, cetuximab, or carboplatin-paclitaxel
Radiation · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 25, 2026, 4:07 PM EDT
Completed Not applicable Interventional

Hybrid Capture 2 Human Papiloma Virus (HPV) High-Risk Anal DNA Test

NCT01104181
View directory record Official record
Conditions
Anal Canal HPV Infection Diagnosis, Anal Dysplasia Diagnosis, Anal Cancer
Interventions
HC2 collection kit with a swab or brush
Device
Lead sponsor
Laser Surgery Care
Other
Eligibility
18 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Oct 25, 2026, 4:07 PM EDT
Completed Phase 2 Interventional Results available

HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma

NCT04369937
View directory record Official record
Conditions
HPV-Related Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Interventions
IMRT (Intensity Modulated Radiotherapy), Pembrolizumab, Cisplatin, ISA101b
Radiation · Drug · Biological
Lead sponsor
Dan Zandberg
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 25, 2026, 4:07 PM EDT
Recruiting Early Phase 1 Interventional

Early Intervention in High Risk CCUS

NCT06802146
View directory record Official record
Conditions
Clonal Cytopenia of Undetermined Significance, Cytopenia
Interventions
Inqovi
Drug
Lead sponsor
Lachelle D. Weeks, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 25, 2026, 4:07 PM EDT
Recruiting Phase 2 Interventional

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

NCT06500273
View directory record Official record
Conditions
Large B-cell Lymphoma
Interventions
cemacabtagene ansegedleucel, Fludarabine, Cyclophosphamide, Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™
Genetic · Drug · Device
Lead sponsor
Allogene Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
63
States / cities
Gilbert, Arizona • Hot Springs, Arkansas • Berkeley, California + 51 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 25, 2026, 4:07 PM EDT
Completed Not applicable Interventional

Identifying At-Risk Patients and Predicting Deterioration of In-Patients Using Continuous Heart Rate, Respiratory Rate, and Movement Monitoring

NCT03010774
View directory record Official record
Conditions
Sleep Quality
Interventions
Risk Stratification, Usual Care
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 27, 2020 · Synced Oct 25, 2026, 4:07 PM EDT
Active, not recruiting No phase listed Observational

AKI and Delirium Risk Prediction and Cost Burden Study

NCT07866560
View directory record Official record
Conditions
Acute Kidney Injury, Delirium
Interventions
It is observational trial with no intervention being evaluated
Other
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
25,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 25, 2026, 4:07 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

SGA for TEE: Safe Alternative to Deep Sedation for Patients With High-risk Cardiopulmonary Disease.

NCT04939220
View directory record Official record
Conditions
Cardiopulmonary Disease
Interventions
TEE with SGA, TEE with Deep Sedation
Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Oct 25, 2026, 4:07 PM EDT
Completed Phase 3 Interventional Results available

SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19

NCT05629962
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection), COVID-19
Interventions
Bemnifosbuvir (BEM), Placebo
Drug
Lead sponsor
Atea Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
61
States / cities
Kingman, Arizona • Prescott, Arizona • Surprise, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Oct 25, 2026, 4:07 PM EDT